PT - JOURNAL ARTICLE AU - J. F. Douglas AU - B. J. Ludwig AU - T. Ginsberg AU - F. M. Berger TI - THE METABOLIC FATE OF MEBUTAMATE (CAPLA) DP - 1962 Apr 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 5--9 VI - 136 IP - 1 4099 - http://jpet.aspetjournals.org/content/136/1/5.short 4100 - http://jpet.aspetjournals.org/content/136/1/5.full SO - J Pharmacol Exp Ther1962 Apr 01; 136 AB - Mebutamate is absorbed rapidly into the bloodstream of man, reaching a peak concentration between the first and second hours after oral administration. The metabolism of mebutamate leads to at least three urinary end-products: unchanged drug present in small quantities, a hydroxylated derivative, 2-methyl-2-(β-hydroxyl-α-methylpropyl)-1,3-propanediol dicarbamate, which is the primary metabolite and a glucuronide conjugate.